Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

104.72 +2.93 (+2.88%)

Streaming Delayed Price Updated: 12:31 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 Next >

Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs

May 04, 2021

From Incyte

Via Business Wire

Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021

May 03, 2021

From Incyte

Via Business Wire

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

Incyte to Present at Upcoming Investor Conference

April 27, 2021

From Incyte

Via Business Wire

Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies ↗

April 23, 2021

Incyte Corporation (NASDAQ: INCY) has announced findings from three pooled analyses of its Phase 3 studies, TRuE-AD1 and TRuE-AD2 evaluating ruxolitinib cream...

Via Benzinga

Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

April 23, 2021

From Incyte

Via Business Wire

Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis

April 23, 2021

From Incyte

Via Business Wire

Multiple Abstracts from Incyte’s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience

April 20, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex ↗

April 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...

Via Benzinga

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

April 19, 2021

From Incyte and MorphoSys AG

Via Business Wire

Incyte to Report First Quarter Financial Results

April 13, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data ↗

April 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) Aclaris Therapeutics, Inc...

Via Benzinga

Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal ↗

April 08, 2021

Eli Lilly And Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) have reported results from the COV-BARRIER Phase 3 study ...

Via Benzinga

The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award ↗

April 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

Topics Intellectual Property

< Previous 1 2

...

19 20 21 22 23 24 25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.